share_log

424B3: Prospectus

424B3: Prospectus

424B3：募資說明書
美股sec公告 ·  06/17 17:30
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics, a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, compared to a net loss of $10.5 million for the previous year. The company's research and development expenses increased by 30.2% to $7.3 million, primarily due to clinical study costs and an increase in employee numbers. General and administrative expenses slightly decreased by 3.9% to $4.8 million. Financing income netted a gain of $1.9 million, mainly from the revaluation of warrants. As of December 31, 2023, NeuroSense had cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, and it has been indicated that existing cash will not suffice for the next 12 months without additional financing. NeuroSense's lead product candidate, PrimeC, is in development for treating neurodegenerative diseases such as ALS, with ongoing clinical trials and regulatory processes. The company has not generated any revenue to date and expects to continue incurring losses as it invests in product development and seeks regulatory approvals.
NeuroSense Therapeutics, a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, compared to a net loss of $10.5 million for the previous year. The company's research and development expenses increased by 30.2% to $7.3 million, primarily due to clinical study costs and an increase in employee numbers. General and administrative expenses slightly decreased by 3.9% to $4.8 million. Financing income netted a gain of $1.9 million, mainly from the revaluation of warrants. As of December 31, 2023, NeuroSense had cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, and it has been indicated that existing cash will not suffice for the next 12 months without additional financing. NeuroSense's lead product candidate, PrimeC, is in development for treating neurodegenerative diseases such as ALS, with ongoing clinical trials and regulatory processes. The company has not generated any revenue to date and expects to continue incurring losses as it invests in product development and seeks regulatory approvals.
臨床階段生物技術公司NeuroSense Therapeutics報告稱，截至2023年12月31日，淨虧損爲1010萬美元，而去年同期淨虧損爲1050萬美元。公司的研發費用增加了30.2％，達到730萬美元，主要是由於臨床研究費用和員工人數增加。總行政費用略有下降，爲480萬美元，降幅爲3.9％。融資收入淨額爲190萬美元，主要來自權證再估值。截至2023年12月31日，NeuroSense的現金及現金等價物爲260萬美元。公司的財務報表是按照持續服務理念編制的，並且已經表明現有的現金不足以在沒有額外融資的情況下支持未來12個月的運作。NeuroSense的主要產品候選者PrimeC正在開發，用於治療諸如漸凍人症等神經退行性疾病，正在進行臨床試驗和監管流程。該公司迄今尚未產生任何營業收入，並計劃繼續投資產品開發和尋求監管批准而繼續產生虧損。
臨床階段生物技術公司NeuroSense Therapeutics報告稱，截至2023年12月31日，淨虧損爲1010萬美元，而去年同期淨虧損爲1050萬美元。公司的研發費用增加了30.2％，達到730萬美元，主要是由於臨床研究費用和員工人數增加。總行政費用略有下降，爲480萬美元，降幅爲3.9％。融資收入淨額爲190萬美元，主要來自權證再估值。截至2023年12月31日，NeuroSense的現金及現金等價物爲260萬美元。公司的財務報表是按照持續服務理念編制的，並且已經表明現有的現金不足以在沒有額外融資的情況下支持未來12個月的運作。NeuroSense的主要產品候選者PrimeC正在開發，用於治療諸如漸凍人症等神經退行性疾病，正在進行臨床試驗和監管流程。該公司迄今尚未產生任何營業收入，並計劃繼續投資產品開發和尋求監管批准而繼續產生虧損。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息